Boehringer Ingelheim Signs a Worldwide License Agreement with Bridge Biotherapeutics for its BBT-877 for $1.28B
Interpace Diagnostics Signs an AI-Driven Agreement with Predictive Oncology for Diagnosing Thyroid Cancer
Shots:
- Bridge to receive $50.66M as up front and near-term payments, up to $1.23B based on development, regulatory, and commercial milestones and royalties on sales
- The focus of the collaboration is to develop Bridge’s BBT-877 candidate and expand BI’s pipeline of fibrosing interstitial lung diseases in developing therapies for patients with Idiopathic Pulmonary Fibrosis (IPF)
- BBT-877 is an autotaxin inhibitor targeted for the treatment of IPF, currently being evaluated in P-I expected to enter P-II within the next 12 months. In 2017, Bridge in-licensed BBT-877 from LegoChem Biosciences
Click here to read full press release/ article | Ref: Boehringer Ingelheim | Image: Australia247